ZA200403482B - Method and pharmaceutical preparations for reducing the activity of cells. - Google Patents
Method and pharmaceutical preparations for reducing the activity of cells. Download PDFInfo
- Publication number
- ZA200403482B ZA200403482B ZA200403482A ZA200403482A ZA200403482B ZA 200403482 B ZA200403482 B ZA 200403482B ZA 200403482 A ZA200403482 A ZA 200403482A ZA 200403482 A ZA200403482 A ZA 200403482A ZA 200403482 B ZA200403482 B ZA 200403482B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- lycopene
- composition
- activity
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 40
- 230000000694 effects Effects 0.000 title claims description 34
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 claims description 110
- 239000000203 mixture Substances 0.000 claims description 91
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 90
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 89
- 235000012661 lycopene Nutrition 0.000 claims description 89
- 239000001751 lycopene Substances 0.000 claims description 89
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 89
- 229960004999 lycopene Drugs 0.000 claims description 89
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 89
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 claims description 55
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 claims description 55
- 235000011765 phytoene Nutrition 0.000 claims description 55
- 201000011510 cancer Diseases 0.000 claims description 53
- OVSVTCFNLSGAMM-KGBODLQUSA-N cis-phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/C=C/C=C(C)/CCC=C(/C)CCC=C(C)C)C)C)C)C OVSVTCFNLSGAMM-KGBODLQUSA-N 0.000 claims description 47
- 235000002677 phytofluene Nutrition 0.000 claims description 47
- OVSVTCFNLSGAMM-UZFNGAIXSA-N phytofluene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 claims description 47
- ZYSFBWMZMDHGOJ-SGKBLAECSA-N phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)C=CC=C(/C)CCC=C(C)C)C)C)C)C ZYSFBWMZMDHGOJ-SGKBLAECSA-N 0.000 claims description 47
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 claims description 47
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 36
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 36
- 235000013793 astaxanthin Nutrition 0.000 claims description 36
- 239000001168 astaxanthin Substances 0.000 claims description 36
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 36
- 229940022405 astaxanthin Drugs 0.000 claims description 36
- 235000013734 beta-carotene Nutrition 0.000 claims description 36
- 239000011648 beta-carotene Substances 0.000 claims description 36
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 36
- 229960002747 betacarotene Drugs 0.000 claims description 36
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 36
- 235000021466 carotenoid Nutrition 0.000 claims description 34
- 150000001747 carotenoids Chemical class 0.000 claims description 34
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 32
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 32
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 32
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 32
- 235000012680 lutein Nutrition 0.000 claims description 32
- 239000001656 lutein Substances 0.000 claims description 32
- 229960005375 lutein Drugs 0.000 claims description 32
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 32
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 32
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 32
- 235000010930 zeaxanthin Nutrition 0.000 claims description 32
- 239000001775 zeaxanthin Substances 0.000 claims description 32
- 229940043269 zeaxanthin Drugs 0.000 claims description 32
- -1 cataxanthin Chemical compound 0.000 claims description 31
- 230000002401 inhibitory effect Effects 0.000 claims description 29
- 230000012010 growth Effects 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 230000003405 preventing effect Effects 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 230000005907 cancer growth Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010073069 Hepatic cancer Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001746 carotenes Chemical class 0.000 claims 1
- 235000005473 carotenes Nutrition 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 230000001093 anti-cancer Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 230000009702 cancer cell proliferation Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- 241000227653 Lycopersicon Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14644901A IL146449A0 (en) | 2001-11-12 | 2001-11-12 | Method and pharmaceutical preparations for reducing the activity of cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200403482B true ZA200403482B (en) | 2005-07-25 |
Family
ID=11075857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200403482A ZA200403482B (en) | 2001-11-12 | 2004-05-07 | Method and pharmaceutical preparations for reducing the activity of cells. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040259959A1 (pl) |
| EP (1) | EP1443914A1 (pl) |
| JP (1) | JP2005513009A (pl) |
| KR (1) | KR20050043784A (pl) |
| CN (1) | CN100408030C (pl) |
| BR (1) | BR0214196A (pl) |
| CA (1) | CA2466508A1 (pl) |
| IL (1) | IL146449A0 (pl) |
| NO (1) | NO20041773L (pl) |
| PL (1) | PL368857A1 (pl) |
| RU (1) | RU2004114282A (pl) |
| WO (1) | WO2003041695A1 (pl) |
| ZA (1) | ZA200403482B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
| KR101482081B1 (ko) | 2005-03-18 | 2015-01-13 | 마이크로비아 인크. | 유질 효모와 진균 내에서 카로티노이드의 생산 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
| EP2078092A2 (en) | 2006-09-28 | 2009-07-15 | Microbia, Inc. | Production of carotenoids in oleaginous yeast and fungi |
| RU2563991C2 (ru) * | 2009-01-19 | 2015-09-27 | Ликоред Лтд | Синергические комбинации каротиноидов и полифенолов |
| ES2583004T3 (es) * | 2010-10-13 | 2016-09-16 | Vigenent Inc. | Olleya marilimosa y su uso en un método para la preparación de una composición que contiene zeaxantina |
| US20130302319A1 (en) * | 2012-05-09 | 2013-11-14 | The New York Eye And Ear Infirmary | Zeaxanthin for tumor treatment |
| US9468609B2 (en) * | 2013-03-19 | 2016-10-18 | Lycored Ltd. | Astaxanthin anti-inflammatory synergistic combinations |
| CA2916759C (en) | 2013-08-08 | 2023-02-28 | Knipbio | Methylotrophs for aquaculture and animal feed |
| EP3079786A1 (en) | 2013-12-06 | 2016-10-19 | DSM IP Assets B.V. | Biomass formulation |
| US9572783B1 (en) * | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| EP3153160B1 (en) * | 2015-10-08 | 2021-08-11 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| CN107049998A (zh) * | 2016-09-20 | 2017-08-18 | 南华大学附属第二医院 | 番茄红素顺式异构体在制备卵巢癌治疗药物中的应用 |
| IT201700005649A1 (it) | 2017-01-19 | 2018-07-19 | Associazione Oncologica Milanese Amo La Vita Onlus | Uso di derivati di carotenoidi per ridurre la tossicità ed aumentare l’efficacia di trattamenti antitumorali anti-egfr |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL103920A (en) * | 1992-11-30 | 2000-07-26 | Makhteshim Chem Works Ltd | Pharmaceutical preparations for inhibiting the growth of cancer cells and use of lycopene for the preparation thereof |
| US5643623A (en) * | 1995-06-07 | 1997-07-01 | Mars Incorporated | Health food product and its uses |
| AUPO693397A0 (en) * | 1997-05-22 | 1997-06-12 | Betatene Limited | Carotenoid formulation |
| DE19838636A1 (de) * | 1998-08-26 | 2000-03-02 | Basf Ag | Carotinoid-Formulierungen, enthaltend ein Gemisch aus beta-Carotin, Lycopin und Lutein |
| EP0984059A1 (en) * | 1998-09-01 | 2000-03-08 | The Procter & Gamble Company | Bleaching compositions |
| WO2001026668A1 (en) * | 1999-10-14 | 2001-04-19 | Unilever N.V. | Compositions with anti-prostate cancer activity |
| IL135335A (en) * | 2000-03-29 | 2013-12-31 | Lycored Natural Prod Ind Ltd | Use of Carotenoids in Preparing Pharmaceuticals to Prevent Adverse Effects from Hormones and Pharmaceuticals Containing Carotenoids |
-
2001
- 2001-11-12 IL IL14644901A patent/IL146449A0/xx unknown
-
2002
- 2002-11-05 RU RU2004114282/14A patent/RU2004114282A/ru not_active Application Discontinuation
- 2002-11-05 PL PL02368857A patent/PL368857A1/pl unknown
- 2002-11-05 WO PCT/IL2002/000876 patent/WO2003041695A1/en active Application Filing
- 2002-11-05 US US10/495,213 patent/US20040259959A1/en not_active Abandoned
- 2002-11-05 KR KR1020047007122A patent/KR20050043784A/ko not_active Application Discontinuation
- 2002-11-05 BR BR0214196-5A patent/BR0214196A/pt not_active IP Right Cessation
- 2002-11-05 CN CNB028270215A patent/CN100408030C/zh not_active Expired - Fee Related
- 2002-11-05 EP EP02781736A patent/EP1443914A1/en not_active Ceased
- 2002-11-05 CA CA002466508A patent/CA2466508A1/en not_active Abandoned
- 2002-11-05 JP JP2003543582A patent/JP2005513009A/ja active Pending
-
2004
- 2004-04-30 NO NO20041773A patent/NO20041773L/no not_active Application Discontinuation
- 2004-05-07 ZA ZA200403482A patent/ZA200403482B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1443914A1 (en) | 2004-08-11 |
| NO20041773L (no) | 2004-06-29 |
| CN1612728A (zh) | 2005-05-04 |
| KR20050043784A (ko) | 2005-05-11 |
| PL368857A1 (pl) | 2005-04-04 |
| CA2466508A1 (en) | 2003-05-22 |
| JP2005513009A (ja) | 2005-05-12 |
| IL146449A0 (en) | 2002-07-25 |
| CN100408030C (zh) | 2008-08-06 |
| BR0214196A (pt) | 2004-08-31 |
| WO2003041695A1 (en) | 2003-05-22 |
| US20040259959A1 (en) | 2004-12-23 |
| RU2004114282A (ru) | 2005-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040259959A1 (en) | Method and pharmaceutical preparation for reducing the activity of cells | |
| JP6125760B2 (ja) | 皮膚を防護するためのカロチノイド組成物及び方法 | |
| White et al. | Pharmacokinetics of beta-carotene and canthaxanthin after ingestion of individual and combined doses by human subjects. | |
| Shklar | Mechanisms of cancer inhibition by anti-oxidant nutrients | |
| US7786175B2 (en) | Anti-atherosclerosis composition containing carotenoids and method for inhibiting LDL oxidation | |
| EP1470817A1 (en) | Compositions for preventing human cancer and method of preventing human cancer | |
| KR20200095476A (ko) | 식물계 지방산 공급원을 포함하는 식이 조성물 | |
| AU2002363613A1 (en) | Carotenoid composition and method for protecting skin | |
| AU2002348711A1 (en) | Method and pharmaceutical preparations for reducing the activity of cells | |
| WO2002005827A2 (en) | Use of natural products in cancer treatment | |
| EP3456208B1 (en) | Agent for improving carotenoid balance in blood | |
| JP2004196782A (ja) | ヒトガン予防方法 | |
| Trivedi et al. | Lycopene–role in health and disease | |
| Padgaonkar et al. | Health Benefits of Natural Mixed Carotenoids | |
| Awad et al. | Anticarcinogenic Activity of Natural and Synthetic Carotenoids |